Company / Cash & Equivalents
Revvity Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$919.9M
FY2025
5-year range
$454.4M / $1.2B
FY2021-FY2025
Trend
-20.9%
vs FY2024
Sector context
#30 of 148
Health Care
What the data says
Revvity's cash & equivalents of $920M is higher than 80% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $163M in FY2018 to $1.2B in FY2024.
Based on SEC 10-K filings.
$920M in FY2025 with a 5-year CAGR of +18.9%. Top quartile in the Health Care sector.
Remained stable around $920M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +26.5%
- 5-Year CAGR
- +18.9%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 148This company $919.9M Sector average $1.2B
▼
-21.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +18.9%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 20.9% year-over-year.
- Ranks #30 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $919.9M | -20.9% |
| FY2024 | $1.2B | +27.4% |
| FY2023 | $913.2M | +101.0% |
| FY2022 | $454.4M | -24.7% |
| FY2021 | $603.3M | +55.9% |
| FY2020 | $387.1M | +101.7% |
| FY2019 | $191.9M | +17.6% |
| FY2018 | $163.1M | -19.3% |
| FY2017 | $202.1M | -43.7% |
| FY2016 | $359.3M | +51.0% |
As of FY2025 · SEC 10-K · Updated Mar 14, 2026